Bonefos and the Consumption of Analgesics. Influence of Clodronate on Analgesics Consumption Among Patients With Bone Metastasis
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Bone Neoplasms
Both
Bone Neoplasms
Trial Information
Bonefos and the Consumption of Analgesics. Influence of Clodronate on Analgesics Consumption Among Patients With Bone Metastasis
Inclusion Criteria:
- Breast cancer or prostate cancer or multiple myeloma.
- Bone metastasis.
- Ability to use analgesics and clodronate 1600 mg/day.
Exclusion Criteria:
- Hypersensitivity to bisphosphonates.
- Clodronate in previous therapy.
- Concomitant use of other bisphosphonates.
- Serious renal insufficiency.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myeloma
Outcome Time Frame:
12 months
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Czech Republic: State Institute for Drug Control
Study ID:
14236
NCT ID:
NCT00909142
Start Date:
April 2007
Completion Date:
February 2009
Related Keywords:
- Bone Neoplasms
- Breast cancer
- Prostate cancer
- Multiple myeloma
- Bone Neoplasms
- Neoplasms
Name | Location |
|---|
